Jacob C Garza

Antidepressant-like effect of low dose ketamine and scopolamine co-treatment in mice.

Neuroscience Letters May 4, 2016 Tracey L Petryshen, Michael Lewis, Kelly A Dennehy et al.

Current medications for depression typically require weeks of treatment before significant clinical improvement is observed, and are only effective in a relatively small subset of patients. Recent human clinical studies have demonstrated that ketamine, an NMDA receptor antagonist, and scopolamine, a muscarinic acetylcholine receptor antagonist, produce rapid antidepressant responses within...